Open Nav

Please submit your session questions in advance at


Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure’s proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure’s lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, Ill. Learn more at

  • Date:Monday, February 11
  • Time:11:15 AM - 11:30 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23312
  • Goal for Presentation:Investor and Pharma Updates
  • Company Website:
  • Company HQ City:Skokie
  • Company HQ State:Illinois
  • Company HQ Country:United States
  • Ticker:XCUR
  • Exchange:OTCQB
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:AST-008 (TLR9 agonist)
  • Development Phase of Primary Product:Phase II
David Giljohann